## Index

Note: Page numbers in *italic* indicate Figures and those in **bold** indicate Tables.

<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2×2 contingency table</td>
<td>487–488</td>
</tr>
<tr>
<td>95% confidence intervals (CIs) and p-values</td>
<td>486</td>
</tr>
<tr>
<td>a-A gradient calculation</td>
<td>10</td>
</tr>
<tr>
<td>abdominal compartment syndrome assessment for</td>
<td>81</td>
</tr>
<tr>
<td>causes and prognosis in neonates and infants</td>
<td>236</td>
</tr>
<tr>
<td>definition and risk factors</td>
<td>314–315</td>
</tr>
<tr>
<td>in resuscitated burn patients</td>
<td>425</td>
</tr>
<tr>
<td>abdominal injury</td>
<td>307–315</td>
</tr>
<tr>
<td>abdominal paracentesis, performance in the ICU</td>
<td>259–260</td>
</tr>
<tr>
<td>AC/VCV ventilation</td>
<td></td>
</tr>
<tr>
<td>auto-PEEP waveform and intervention to correct</td>
<td>87, 87</td>
</tr>
<tr>
<td>high peak airway pressures in a postoperative patient</td>
<td>83–84</td>
</tr>
<tr>
<td>intervention to improve oxygenation</td>
<td>82</td>
</tr>
<tr>
<td>waveform analysis</td>
<td>88, 88</td>
</tr>
<tr>
<td>acetaminophen</td>
<td></td>
</tr>
<tr>
<td>clinical manifestations of acute intoxication</td>
<td>175</td>
</tr>
<tr>
<td>features of hepatotoxicity</td>
<td>174–175</td>
</tr>
<tr>
<td>mortality in the United States</td>
<td>240</td>
</tr>
<tr>
<td>NAC antidote administration</td>
<td>240</td>
</tr>
<tr>
<td>prevention of hepatotoxicity in overdose</td>
<td>240</td>
</tr>
<tr>
<td>treatment of acetaminophen poisoning</td>
<td>175</td>
</tr>
<tr>
<td>acetylcholine, role in development of delirium</td>
<td>129</td>
</tr>
<tr>
<td>acid-base balance</td>
<td>135–144</td>
</tr>
<tr>
<td>acid-base disorders</td>
<td></td>
</tr>
<tr>
<td>caused by vomiting</td>
<td>136</td>
</tr>
<tr>
<td>diabetic ketoacidosis</td>
<td>141</td>
</tr>
<tr>
<td>diagnosis of metabolic acidosis</td>
<td>137</td>
</tr>
<tr>
<td>non-anion gap type metabolic acidosis</td>
<td>140</td>
</tr>
<tr>
<td>see also metabolic acidosis; metabolic alkalosis</td>
<td></td>
</tr>
<tr>
<td>acid burns, treatment</td>
<td>430</td>
</tr>
<tr>
<td>acidosis, “lethal triad” of coagulopathy, acidosis, and hypothermia</td>
<td>117</td>
</tr>
<tr>
<td><em>Acinetobacter</em> species, beta-lactamase production</td>
<td>105</td>
</tr>
<tr>
<td>activity scales</td>
<td>75</td>
</tr>
<tr>
<td>acute adrenal dysfunction, signs and symptoms</td>
<td>146–147</td>
</tr>
<tr>
<td>acute carpal tunnel syndrome, management</td>
<td>324–325</td>
</tr>
<tr>
<td>acute coronary syndrome with DAPT, timing of future surgery</td>
<td>33–34</td>
</tr>
<tr>
<td>acute coronary syndromes</td>
<td>33–50</td>
</tr>
<tr>
<td>acute decompensated heart failure (ADHF)</td>
<td>8, 9</td>
</tr>
<tr>
<td>acute fatty liver of pregnancy (AFLP), diagnosis and treatment</td>
<td>219–220</td>
</tr>
<tr>
<td>acute head injury, initial management</td>
<td>277–279</td>
</tr>
<tr>
<td>acute kidney injury (AKI)</td>
<td>159–167</td>
</tr>
<tr>
<td>advantages of renal replacement therapy</td>
<td>165–166</td>
</tr>
<tr>
<td>criteria for stage 3 AKI</td>
<td>159–160, 160</td>
</tr>
<tr>
<td>definition</td>
<td>159, 160</td>
</tr>
<tr>
<td>determining the cause using FENa and FEUrea</td>
<td>166–167</td>
</tr>
<tr>
<td>diagnosis of intrinsic and prerenal causes</td>
<td>163–164</td>
</tr>
<tr>
<td>diagnosis of prerenal disorders</td>
<td>166</td>
</tr>
<tr>
<td>distinguishing intrinsic and prerenal causes</td>
<td>164</td>
</tr>
<tr>
<td>distinguishing renal and prerenal disorders</td>
<td>166–167</td>
</tr>
<tr>
<td>drugs associated with</td>
<td></td>
</tr>
<tr>
<td>effects of dopamine</td>
<td>165</td>
</tr>
<tr>
<td>effects of furosemide</td>
<td>164–165</td>
</tr>
<tr>
<td>etiologies</td>
<td>76</td>
</tr>
<tr>
<td>FENa calculation</td>
<td>166</td>
</tr>
<tr>
<td>indications for acute dialysis</td>
<td>162–163</td>
</tr>
<tr>
<td>indications for dialysis</td>
<td>161–162</td>
</tr>
<tr>
<td>initial workup for postoperative oliguria</td>
<td>160–161</td>
</tr>
<tr>
<td>KDOGO criteria stages of AKI</td>
<td>159–160, 160</td>
</tr>
<tr>
<td>nutritional management</td>
<td>167</td>
</tr>
<tr>
<td>potential perioperative causes</td>
<td>161</td>
</tr>
<tr>
<td>prevention of contrast-induced nephropathy (CIN)</td>
<td>163</td>
</tr>
<tr>
<td>risk factors in pediatric ICU patients</td>
<td>233</td>
</tr>
<tr>
<td>risk in elderly trauma patients</td>
<td>468–469</td>
</tr>
<tr>
<td>signs and symptoms of hyperkalemia due to stage 3 AKI</td>
<td>163</td>
</tr>
<tr>
<td>treatment of traumatic rhabdomyolosis</td>
<td>162</td>
</tr>
<tr>
<td>acute liver failure, clinical features and mortality risk</td>
<td>173–174</td>
</tr>
</tbody>
</table>
acute lung injury (ALI)
associated with transfusion
(TRALI) 110
pulmonary edema 14
acute pericarditis 39–40, 39, 40
acute phase proteins (APP)
functions of negative APPs
178–179
mediators involved in production
of 177–178
response to severe injury 177
acute phase response (APR) 177
acute respiratory distress syndrome
(ARDS)
additional therapies to decrease
mortality 86–87
diagnosis in children
459–461, 460
differences between pediatric and
adult ARDS 229, 229
ECMO for ARDS 30
effect of PEEP in a severely hypoxic
patients 6
immunonutrition
recommendations 183–184
location of optimal PEEP on a
volume-pressure curve 13
pediatric patient see pediatric acute
respiratory distress syndrome
(PARDS)
position therapy for severe
ARDS 29–30
pulmonary edema 14
transmembrane fluid flux 14
acute respiratory failure and mechanical
ventilation 79–88
acute stent thrombosis, diagnosis and
treatment 440
acute tubular necrosis, diagnostic
criteria 160
Addisonian crisis, signs and
symptoms 146–147
adnexal torsion, diagnosis and
treatment 431
adrenal insufficiency, after traumatic
brain injury 148
Advanced Trauma Life Support
(ATLS) protocol, control of
active bleeding 328–329
*Aeromonas* species, diagnosis of
NSTI caused by 412
age-related changes see elderly
patients
air leaks, sources in trauma patients
300–301
airway management 69–78
emergency airway in pediatric
patients 297
pediatric trauma patients 453
pregnant trauma patient 355
tracheal injury 297
airway pressure release ventilation
(APRV), effects on
oxygenation 82–83
albumin
effect on anion-gap type metabolic
acidosis 143
use in pediatric burn patients
227–228
alcohol dependence
risk of critical illness 133
risk of hospital mortality 133
alcohol withdrawal pathophysiology
132–134
neurotransmitters responsible
for 132
treatment 132–133, 133
alkali burns, initial treatment 430
alpha error 485
alvimopan (Entereg), prescribing
limitations 98–99, 98
American Academy of Orthopedic
Surgery (AAOS), guidelines for
PE and bleeding prophylaxis
205–206, 206
American College of Chest Physicians
(ACCP), VTE prevention
and treatment guidelines
205, 206
American Heart Association (AHA)
guidelines for CPR 15
recommendations for sudden
cardiac arrest 17
American Pediatric Surgical
Association (APSA), guidelines for pediatric blunt
trauma injury 234–235, 234
American Society of Anesthesiologists
(ASA), classification of
physical status 71
American Society of Regional
Anesthesia and Pain Medicine
(ASRA), guidelines on
LMWHs and epidurals 204
amino acids
administration of branched-chain
amino acids in critically-ill
patients 183
functions of arginine 180
functions of glutamine 178
functions of glutamine 180
requirements of critically-ill and
injured patients 179
amiodarone 15–16
amniotic fluid embolism, diagnosis
and treatment 221
amniotic fluid embolism syndrome
(AFES)
coagulopathy associated
with 435
development of disseminated
intravascular coagulation
(DIC) 435
diagnosis and management
434–435
amphotericin B, advantages of lipid
formulations 102
amphotericin B deoxycholate, renal
toxicity 102
amputation, risk in combined skeletal
and arterial injuries
333–334, 334
analgesia 121–128
delirium prevention
strategies 130
postoperative pain in a patient with
kidney disease 122
anesthesia 121–128
causes of continued paralysis
70–71
indicators of malignant
hyperthermia 126
malignant hyperthermia (MH)
77–78
postdural puncture headache
125–126
anesthetic agents
for patients with liver disease 124
for patients with previous
gastrectomy 124
for patients with vitamin B12
deficiency 124
potential hepatotoxicity 124
respiratory depression side
effect 128
angiotensin receptor blockers
(ARB) 147
ANOVA 485
anterior mediastinal mass, anesthetic
considerations 443
antibiotic resistance
avoiding misuse and overuse of
antibiotics 103–104
extended-spectrum beta-lactamase (ESBL) microorganisms 95–96
mechanisms related to beta-lactamase production 105–106
risk factors for MDR pneumonia 96
antibiotics 100–108
black box warnings 108
choice based on risk of MDR VAP 104–105
duration of antibiotic therapy 90
effect on outcomes of sepsis 56
for ESBL organisms 105
for necrotizing soft tissue infection 95, 106–107
indications for combination therapy 92–93
interactions between NMBAs and aminoglycoside antibiotics 70–71
polype antibiotic family 102
principles of antibiotic therapy 103–104
prophylactic antibiotics in critically-ill patients 93
treatment of extended-spectrum beta-lactamase-producing organisms 53
anticoagulants 99–100
anticoagulated trauma patients management for surgery 33–34
management of intracranial hemorrhage following TBI 285–286
management of patients with HIT 100–101
patients with cirrhosis 210–211
rapid reversal of anticoagulation 118–119
rapid reversal of coagulopathy 114
antidepressant overdose, clinical presentation of TCA toxicity 239–240
antidiuretic hormone (ADH) deficiency following traumatic brain injury 145
lack of ADH release in central diabetes insipidus 135
antifungals, treatment for cryptococcal meningitis 53–54
antiemetics, choice for critically-ill patients 99
antioxidants, supplementation in critically-ill patients 182–183
antiphospholipid syndrome (APS), diagnosis and management 207
antiplatelet therapy, perioperative management 116–117
antithrombin III deficiency 26
antithymocyte antibodies, side effects when used as induction agents 216–217
aortic dissection management of limited dissection 442
presentation 442
secondary complications 442
aortic injury CXR findings 272
diagnosis following blunt trauma 304
diagnosis of traumatic aortic injury 305
treatment for traumatic aortic injury 305
APACHE II prognostic model, applications 169
APACHE III prognostic model, applications 169
apixaban, rapid reversal in trauma patients 118–119
appendicitis diagnosis 376
guidelines for laparoscopic appendectomy in pregnant patients 434
management options 376–377
presentation and diagnosis in pregnancy 433
treatment in elderly patients 470–471
treatment of acute appendicitis in pregnancy 433–434
appendix 371–383
carcinoid tumor 373
pseudomyxoma peritonei symptoms and treatment 373
ARDS see acute respiratory distress syndrome arginine, requirements in trauma and critical care patients 180
arrhythmias 33–50
multifocal atrial tachycardia (MAT) 80
arterial catheterization complications 254
indications for 254
arterial line catheters, effects of increasing distance from the heart 61
ascites, treatment for intractable ascites in cirrhosis 173
asthma attack, respiratory failure and cardiomyopathy 36
asymmetric (skewed, non-parametric) distribution 484, 488
atelectasis, signs of 80
atracurium
Hofmann elimination 97, 98
reversal drugs 107
atracuronium, mechanism of action 123
atrial fibrillation, management in elderly patients 472–473
atrial flutter 42–44
atrial thrombus 43
attributable risk 487–488
autonomy principle 491, 493
competence to make decisions 493–494
right to choose therapy and who will deliver it 495–496
auto-PEEP, waveform and intervention to correct 87, 87
Avalon Elite BiCaval Dual Lumen catheter, complications 28–29
bacterial endocarditis, diagnosis and treatment 447–448
barbiturate therapy, use in management of traumatic brain injury 194–195
bariatric surgery 415–422
causes of early mortality 420
recommendation for obesity 415
beneficence principle 491, 493, 499
benzamides, antiemetic action 99
benzocaine, methemoglobinemia associated with 140
benzodiazepines
mechanism of action 101–102
treatment of overdose 101–102
use in the ICU for sedation 101–102
beta blockers
overdose symptoms and management 247
role in postoperative myocardial infarction prevention 73
beta error 485
beta-lactam antibiotics 95–96
beta-lactamase inhibitors 105–106
beta-lactamases, microorganisms that produce 105–106
Bezold–Jarisch reflex 48
bile duct injury
factors in successful reconstruction 385
iatrogenic injury 385
bile duct stones, MRCP imaging 266–267
biliary anatomy 388
biliary infection, empiric treatment regimen for specific patient populations 387
bladder injury
associated with pelvic fractures 318, 318
extraperitoneal injury management 338
management of penetrating injury 337, 338
bleeding risk, prophylaxis for total knee or hip replacement 205–206, 206
blood component therapy for transfusion 109
blood glucose control, multiply-injured trauma patient 146
blunt abdominal trauma
APSA guidelines for pediatric solid organ injury 234–235, 234
CT scan evaluation 263
hepatic or splenic blush on CT scan in pediatric patients 231
management of injuries in pediatric patients 235, 462
management of pediatric blunt kidney trauma 235
management of pediatric liver or spleen injury 234–235, 234
non-accidental trauma in young children 235
small bowel mesenteric injury 379–380, 379
blunt cardiac injury (BCI), screening tools 304
blunt cerebrovascular injury (BCVI) 288–289, 289, 289
diagnosis and management 277, 278
diagnostic imaging 268
indications for BCVI screening 290
indications for endovascular interventions 290–291, 290
injury scale 290–291, 290
blunt neck trauma 287–297
blunt trauma, splenic artery embolization caused by 263–264
blunt vertebral artery injury, diagnosis and management 277, 278
body mass index (BMI)
calculation 415
changes related to aging 472
classification 415, 416
Boerhaave's syndrome, diagnosis and treatment 359–360
Bowel Injury Prediction Score (BIPS) 379–380
bowel obstruction
gallstone ileus 388–389
Meckel's diverticulum 377, 377
bowel perforation, symptoms in steroid-treated patients 149
brachial artery injury
evaluation and management 330
presentation 330
brain death
criteria for declaration 494–495
nonrational requests from the family 495
brain injury see traumatic brain injury
brain oxygenation monitoring techniques 195
Brain Trauma Foundation, Guidelines for the management of severe traumatic brain injury 198
branched-chain amino acids (BCCAAs), administration in critically-ill patients 183
broken heart syndrome 36
bronchopleural fistula (BPF), complication of lung resection 441
bronchoscopy
for diagnosis of ventilator-associated pneumonia 258
for Zone II penetrating neck trauma 294
Brugada syndrome 35–36, 35
bupivacaine (Marcaine), mechanism of action 72
burn shock pathophysiology 423
burns 423–430
abdominal compartment syndrome monitoring and treatment 425
albumin use in pediatric patients 227–228
area assessment 424
bladder pressure monitoring 425
burn center transfer criteria 428
burn shock pathophysiology 423
compartment syndrome diagnosis 425–426
compartment syndrome management 425–426, 426
compartment syndrome risk in circumferential burns 425–426
compromised chest wall movement and ventilation 85
deep second- and third-degree burns 429
elderly patients 473–474
escharotomy for compartment syndrome 425–426, 426
fluid resuscitation of burn patients 423
full-thickness circumferential burns of the torso 85
hyperkalemia risk 122
infection risk from central line catheters 426–427
inhalational injury treatment 428
initial resuscitation of burn victims 423
neuromuscular blocker choice for intubation 122
nutritional requirements of burn patients 427
nutritional therapy for burn patients 188
parenteral nutrition in severe burn patients 427
pediatric patients 462–463
percentage total body surface area involved 424
potentially beneficial additional treatments 427
resuscitation monitoring 424–425
“rule of nines” used in area assessment 424
scald burn treatment in a pregnant patient 436
sequelae of initial burn injury 423
side effects of topical antimicrobials 427–428
signs of infection 426
thoracic escharotomy 85
topical agent for burned ear with exposed cartilage 429
topical antimicrobials 429
butyrophenones, antiemetic action 99
C1 fracture, Jefferson fracture 295, 295
C2 fracture, association with vertebral artery injury 295–296, 295
caffeine, mechanism of action 250–251
calcineurin inhibitors
adverse effects 210, 215
mechanisms of action 214–215
calcineurin toxicity, caused by drug-drug interactions 209–210, 210
Candida glabrata, antibiotic resistance 96
Candida species
association with CRBSI 63
intravascular infection risk factors and treatment 56
candidemia in critically ill patients, treatment 56
candidiasis
invasive, empiric antifungal therapy 106
postoperative, antibiotic prophylaxis 93
risk factors in critically-ill patients 106
candiduria in critically ill patients, treatment 56
“cannot intubate, cannot oxygenate” (CICO) scenario 293–294
CaO₂ (oxygen content) of blood, calculation 18
carbapenem-resistant microorganisms 95–96
carbapenems, action against ESBL organisms 105
carbon monoxide (CO) poisoning mechanism 242
symptoms, treatment, and outcomes 242
carcinoid tumor of the appendix 373
cardiac allograft vasculopathy (CAV) distinction for coronary artery disease (CAD) 213
medications to decrease CAV 213–214
cardiac arrest
AHA recommendations for sudden cardiac arrest 17
AHA treatment guidelines 15
positive predictors of survival 15
suspected cardiac etiology 17–18
underlying causes of PEA arrest 16
unstable patient requiring pressor support 17–18
ventricular fibrillation following MI 49–50, 49
ventricular fibrillation treatment in the field 15–16
cardiac arrhythmias, management in elderly patients 472–473
cardiac cycle events 7–8, 7
cardiac injury
mitral valve tenea corda disruption 301
posttraumatic signs of internal cardiac injuries 301
prognostic indicators for penetrating injury 303
repair of cardiac laceration 303–304
screening for blunt cardiac injury (BCI) 304
cardiac pacing, temporary transvenous cardiac pacemaker 255
cardiac pressure-volume loops, physiologic processes represented 4, 4
cardiac surgery, postoperative cardiac tamponade 442–443
cardiac tamponade diagnosis following penetrating injury 299–300
following cardiac surgery 442–443
cardiac transplantation
cardiac allograft vasculopathy (CAV) diagnosis 213
medications to decrease CAV 213–214
cardiogenic shock
features and etiology 20
role of endothelin-1 58
cardiopulmonary resuscitation see CPR
cardiovascular injury 299–306
cardiopulmonary collapse, indications for ED thoracotomy (EDT) 304–305
cardiopulmonary resuscitation see CPR
cardiovascular physiology 3–14
cardiopulmonary collapse 439–451
cardiovascular system, age-related changes 469
cardioversion, medications given after 41–42, 41–42
carotid cavernous fistula diagnosis 275, 276
initial treatment and management 275
carpal tunnel symptoms, related to distal radius fracture 324–325
case-control studies 486–487
catheter-associated urinary tract infection (CAUTI), risk factors 93–94
catheter-directed thrombolytics (CDT) for DVT 201
catheter-related bloodstream infections (CRBSI)
common causative organisms 63
guidelines for prevention 62
prevention practices 94
treatment 53
catheterized critically-ill patients, Candida infection risk and treatment 56
caucus substance ingestion
esophageal injuries 449–450
evaluation of injuries 365
initial assessment and management 365–366
cecal volvulus, diagnosis and management 378, 378
ceftazidime, antimicrobial action 105
cefpodoxime, antimicrobial action 105
ceftazidime, antimicrobial action 105
cefpodoxime, antimicrobial action 105
cell biology 209–217
### Index

- **central cord syndrome, association with falls in the elderly** 193
- **central diabetes insipidus after traumatic brain injury** 145–146
- **free water deficit** 135
- **pathophysiology and treatment** 135
- **central line catheters, managing infection risk in burn patients** 426–427
- **central nervous system infections, antifungal treatment** 53–54
- **central pontine myelinolysis** 139
- **central venous catheter (CVC), timing of intravascular pressure measurement** 66–67
- **central venous catheter (CVC) placement** 62
- **prevention of central line-associated bloodstream infection (CLABSI)** 253
- **ultrasound guidance** 270–271
- **ultrasound guidance versus the landmark technique** 253–254
- **central venous pressure (CVP)** 66
- **cause of acute rapid rise** 66
- **definition** 66
- **cerebral artery aneurysm rupture causing subarachnoid hemorrhage** 192
- **vasospasm following surgical or endovascular management** 192
- **cerebral blood flow, zone of normal cerebral autoregulation** 196
- **cerebral perfusion pressure (CPP), optimizing in traumatic brain injury** 196, 283–284
- **cerebral salt wasting syndrome (CSW)** 139
- **cerebrospinal fluid (CSF), penetration by antifungals** 53–54
- **cerebrospinal fluid (CSF) rhinorrhea, tests to detect** 276
- **cervical esophageal injury evaluation** 361–362
- **operative repair** 362
- **cervical necrotizing fascitis, causes and treatment** 413–414
- **cervical spinal cord injury initial management of blunt injuries** 195
- **pulmonary function testing** 288
- **cervical spine, normal anatomical variation in children** 457
- **cervical spine clearance in elderly patients** 474
- **timing of 296–297
- **cervical spine injury, diagnosis in children** 457
- **Cesarean section in trauma patient undergoing CPR** 436–437
- **prophylactic antibiotics** 225
- **CHADS2 score** 33
- **CHADS2–VASc score** 33
- **chemotherapy neutropenia complication** 54
- **neutropenic enterocolitis complication** 375
- **chest compartment syndrome, signs and treatment** 84–85
- **chest trauma indications for urgent/emergent thoracotomy** 303
- **retained hemothorax** 306
- **widened mediastinum following blunt trauma** 304
- **chest tube, sources of air leaks in trauma patients** 300–301
- **child abuse, signs of non-accidental trauma** 458
- **child protection services, notification of suspected child abuse** 458
- **Child–Turcotte–Pugh (CTP) prognostic model** 169
- **chi-square test** 484
- **cholecystectomy indications for prophylactic procedure** 385–386
- **laparoscopic method** 385
- **choledocholithiasis management in pregnancy** 389
- **treatment in Roux-en-Y gastric bypass patient** 417–418
- **Chvostek's sign** 145
- **ciprofloxacin, use in VAP** 104–105
- **cisatracurium Hofmann elimination** 97, 98
- **mechanism of action** 122
- **metabolism and elimination** 72
- **reversal drugs** 107
- **use for patients with liver or renal disease** 122–123
- **Citrobacter species, beta-lactamase production** 105
- **clindamycin, interaction with neuromuscular blocking agents** 70–71
- **Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)** 133
- **Clinical Pulmonary Infection Score (CPIS)** 90
- **clopidogrel** 44
- **Clostridium difficile, postoperative infection management** 89–90
- **Clostridium difficile colitis management** 372
- **treatment of refractory infection** 100
- **coagulation** 109–119
- **diagnosis and treatment of disseminated intravascular coagulation (DIC)** 114
- **etiology of excessive bleeding after trauma or surgery** 115
- **rapid reversal of anticoagulation in trauma patients** 114, 118
- **coagulation system, role in the sepsis-induced inflammatory cascade** 57
- **coagulopathy bleeding in uremic patients** 116
- **“lethal triad” of coagulopathy, acidosis, and hypothermia** 117
- **cocaine intoxication symptoms and treatment** 246–247
- **mechanism of action** 250–251
- **cocaine-associated chest pain (CACP), evaluation and management** 246–247
- **cohort studies** 483, 483
- **colon** 371–383
- **management of Clostridium difficile colitis** 372
postoperative complications of destructive colon injuries 311

treatment of intraperitoneal gunshot wounds 375

colon tumor
chemotherapy for metastases 376
symptoms and management 376

colonic pseudo-obstruction, treatment 374

communication failures, risk factor for wrong-site surgical procedures 73

compartment syndrome
indication for a therapeutic decompressive fasciotomy 333
indications in closed tibia and fibula fracture 321
length of fasciotomy incision for the leg 322, 322
management in burn patients 425–426, 426
medical malpractice liability issues 321–322
of the chest 84–85
pressure threshold for decompression 322
risk in burn patients 425–426
see also abdominal compartment syndrome
compensatory anti-inflammatory response syndrome (CARS) 178–179
complicated skin and soft tissue infections (cSSTIs) antibiotic choice 410–411
management 409
types of 409
component separation technique, for hernia repair 405
computed tomography see CT confidence intervals (CI) in statistics 484
confounding in studies 487, 488
Confusion Assessment Management (CAM) tool 130, 131
consequentialism 495
continuous renal replacement therapy, for volume status management 340
contrast-induced nephropathy (CIN) 76
prevention in elderly trauma patients 468
prevention strategies 163

CO-oximetry
blood constituents measured by 60
measurement of oxygen saturation (SpO2) 59–60
COPD exacerbations, use of NIPPV 86
core body temperature, at levels of hypothermia 154
coronary artery bypass grafting (CABG), for acute coronary syndrome 44
coronary artery disease (CAD) distinction from cardiac allograft vasculopathy (CAV) 213
smoking risk factor 49
corticosteroids, indications for use in septic shock 52
Cox proportional hazard ratio 487
CPR (cardiopulmonary resuscitation) 15–21
American Heart Association guidelines 15
percentage of myocardial and cerebral blood flow provided by 16–17
CRBSI see catheter-related bloodstream infections
cricothyrotomy predictors of difficult cricothyrotomy 69
SMART assessment tool 69
critical oxygen delivery 13–14
critically-ill patients
Candida intravascular infection risk and treatment 56
factors in successful fluid resuscitation 65–66
nutritional support 77
optimizing oxygen delivery (DO2) 65
pharmacokinetic and pharmacodynamic principles 102–103
refeeding syndrome (RFS) 77
role of lactate clearance in successful fluid resuscitation 65–66
cross-sectional studies 483
cryptococcal meningitis, antifungal treatment 53–54
CT (computed tomography) evaluation of blunt abdominal trauma 263
reducing radiation dose in children 464

CT angiography
blunt vertebral artery injury 277, 278
diagnostic evaluation of penetrating neck trauma 265
CT arteriography, use in penetrating peripheral vascular trauma 265–266
Cushing’s syndrome 147
CXR, findings in traumatic aortic injury 272
cyanide toxicity associated with nitroprusside treatment 247–248
symptoms and treatment 247–248
cyclizine, antiemetic action 99
cyclosporine immunosuppression in transplant patients 210
mechanism of action 214–215
side effects 215
cystoprostatectomy, postoperative complications 339, 339
cytokine release syndrome, management in transplant patients 216–217
cytomegalovirus (CMV) infection opportunistic infection in immunosuppressed patients 93
treatment in transplant patients 215–216
d
D-dimer, diagnostic use in DVT and PE 203–204
dabigatran, rapid reversal in trauma patients 118–119, 118
dalteparin, prophylactic use 203
damage-control laparotomy (DCL), concept and indications 312
damage-control surgery (DCS), aim of the second phase 313
data analysis, descriptive analyses 484, 484
decompressive craniectomy, in traumatic brain injury 283–284
decompressive craniotomy, for traumatic intracranial hypertension 197–198
DECRA trial (2011) findings 197–198
deep vein thrombosis see DVT

delirium 129–134

causes and risk factors 129

Confusion Assessment Management (CAM) tool 130, 131

DSM-V diagnostic criteria 129

effects of medications 131

incidence in hospital and the ICU 129

long-term risks associated with 131–132

medications to avoid 467–468

prevention strategies in the ICU 130, 467

primary evaluation and management 130, 131

delirium tremens

RASS evaluation 133, 133

signs and symptoms 132

treatment of alcohol withdrawal 132–133, 133

Denver screening criteria for blunt cerebrovascular injury (BCVI) 288–289, 289, 289

deontology 491, 495

depression in elderly people, suicide risk of tricyclic antidepressants (TCAs) 471

descriptive analyses, features of 484, 484

desflurane, metabolism 124

desomorphine (Krokodil), effects of use as alternative to heroin 248–250

dexmedetomidine, mechanism of action 102, 121–122, 128

diabetes insipidus (DI), after traumatic brain injury 145–146

diabetic foot infections

predominant pathogens associated with 413

presentation of severe SSTIs 413

diabetic ketoacidosis

presentation and assessment 141

treatment in addition to insulin 150

diagnostic imaging 261–272

dialysis, indications for acute dialysis 162–163

diaphragmatic injury, detection following penetrating trauma 301

diazepam, mechanism of action 128

Dieulafoy’s lesion, diagnosis and management 368

diffuse axonal injury, diagnosis 282

digitalis toxicity, association with electrolyte abnormalities 138, 138

dilaudid, mechanism of action 128

diltiazem, drug–drug interactions 209–210, 210
diphenhydramine, antiemetic action 99

disseminated intravascular coagulation (DIC) associated with amniotic fluid embolism syndrome (AFES) 435
diagnosis and treatment 114
distributive justice 491, 493
diverticulitis, management according to the Hinchey staging system 371

DO₂ (oxygen delivery) calculation 18
dobutamine, mechanism of action of vasodilatory effects 62
domperidone, antiemetic action and side effects 99
drug–drug interactions in transplant patients 209–210, 210

neuromuscular blocking agents and aminoglycoside antibiotics 70–71

drugs associated with acute kidney injury (AKI) 165
droperidol, antiemetic action and side effects 99
eCG, multifocal atrial tachycardia (MAT) 80
echocardiography, surgeon-performed in the ICU 271–272

ECMO (extracorporeal membrane oxygenation) 23–31

bleeding from a previously non-draining chest tube 27–28

causes of acute change 31

choice between VA ECMO and VV ECMO 30

cogulopathy associated with 26

correcting acid-base abnormality 26–27

criteria for use in respiratory failure 29–30

distance between cannulas in VV ECMO 30

factors affecting patient survival 24–26, 25

Harlequin Syndrome 23–24, 29

in ARDS with sepsis 30

indicator of time to trial off ECMO 27

management of bleeding 27–28

patient selection 24–26, 25

pediatric patient consequences of malpositioned veno-venous cannula 237–238, 238

management of massive hemothorax 236–237, 237

verification of correct placement of a veno-venous cannula 237–238, 238

rate of sweep gas in the ECMO circuit 26–27
recognising adequate support 24
relative contraindications 23
RESP score 25–26, 25
role in respiratory failure management 87
signs and causes of recirculation 30
use in acute hypoxic respiratory failure in trauma patients 26
veno‐arterial ECMO 23–24
veno‐venous ECMO 23–24
ectopic pregnancy
presentation and diagnosis of ruptured ectopic pregnancy 431–432
risk factors 431–432
treatment of ruptured ectopic pregnancy 431–2
edema, resuscitation fluids which promote edema 143–144
edrophonium, cholinesterase inhibitor 107, 108
eFAST (extended focused assessment sonography for trauma), injuries detected by 262–263
EKG
left axis deviation 37–38
measuring SR elevation 39–40, 39, 40
ST segment elevation and PR segment elevation 39–40, 39, 40
elderly patients
age‐related cardiovascular changes 465, 469
age‐related changes in nutrition and metabolism 472
appendicitis 470–471
cardiac arrhythmias 472–473
decision‐making by surrogates 469–470
nutritional support in critical illness 471–472
presentation of peptic ulcer disease 470
prevalence and etiologies of syncope 473
prevalence of H. pylori infection 470
suicide rates 471
TCA overdose 471
elderly trauma patients
avoiding delirium in the ICU 467–468
burn injuries 473–474
cervical spine clearance 474
effects of use of warfarin 466–467
incidence and consequences of rib fractures 465–466
loss of upper extremity motor function after a fall 193
mechanical ventilation 466
patient refusal of surgery 469–470
rapid reversal of anticoagulation 466–467
renal dysfunction 468–469
electrolyte abnormalities associated with digitalis toxicity 138, 138
associated with massive transfusion 113–114
caused by vomiting 136
diagnosis of hyponatremia 176
electrolytes 135–144
Eliquis see apixaban
emergency department thoracotomy (EDT), indications for 304–305
end‐diastolic volume 4, 4
end‐of‐life care 491–499
patient who may have impaired judgment 493–494
substituted judgment 491, 493–494
end‐organ profusion, ways to promote 4–5
endocarditis, diagnosis and treatment 447–448
endocrinopathies 145–151
endothelin‐1, role in cardiogenic shock 58
endothelial intubation emergent intubation in pediatric patients 453–454
techniques for successful intubation 256
enoxaparin
administration for pulmonary embolism 99–100
VTE prophylactic dosing and monitoring 207
enteral nutrition (EN)
biochemical derangement in refeeding syndrome (RFS) 77
delivery in the ICU 186
in the critically‐ill patient 77
monitoring in the ICU 186
tolerance in pediatric critical care patients 232
Enterig (alvimopan), prescribing limitations 98–99, 98
Enterobacter species
antibiotic to treat extended‐spectrum beta‐lactamase‐producing strains 53
association with CRBSI 63
association with VAP 55, 96
beta‐lactamase production 105
Enterococcus species, association with CRBSI 63
envenomations 239–251
edipidal analgesia, and LMWHs 204
edipidal hematoma diagnosis 281
surgical management of acute hematoma 281
epigastric blunt injury, management of multiple injuries in children 461–462, 461, 461
epinephrine 15
error types in statistics 485–486
ESBL see extended‐spectrum beta‐lactamase
escharotomy, for compartment syndrome in burn patients 425–426, 426
Escherichia coli, antibiotic regimen for ESBL E. coli 95–96
esophageal balloon catheter values, interpretation 11
esophageal injury
caustic substance ingestion 449–450
cervical esophageal injury repair 362
esophageal laceration repair 292
evaluation of cervical esophageal injury 361–362
gunshot wounds 364–365
management approaches 292–293
esophageal perforation
antibiotic regimen 360–361
Boerhaave's syndrome diagnosis and treatment 359–360
causes 449, 449
iatrogenic 360, 449, 449
morbidity and mortality rates 360
esophageal varices, prevention of variceal bleeding 172
esophagogastric anastomosis, diagnosis of anastomotic leak 450
esophagoscopy, for Zone II penetrating neck trauma 294
esophagus 359–369
anatomy 359
blood supply 359
ethical parity 491
ethical principles 491
ethics 491–499
ethylene glycol ingestion, toxicity and treatment 243
etomidate
influence on postoperative outcome 150
inhibition of adrenal steroid production 124–125
risk of adrenal insufficiency 150
extended-spectrum beta-lactamase (ESBL) organisms antibiotic regimen for ESBL
Escherichia coli 95–96
antibiotics to treat 53
choice of antimicrobial treatment 105
extracorporeal membrane oxygenation see ECMO
extraperitoneal penetrating trauma management 382
extraperitoneal rectal injuries, recommended treatment 313–314
extubation
determinants for safe extubation 85–86
negative pressure pulmonary edema 79–80
use of the rapid shallow breathing index (RSBI) 85–86
Factor V Leiden mutation, perioperative risk 205
falling, history of 36–37, 37
falls in the elderly, central cord syndrome 193
family of deceased, nonrational requests from 495
fasciotomy
length of incision to decompress the leg compartments 322, 322
predictors of the need for 333
FAST exam (Focused Assessment with Sonography for Trauma), sensitivity and specificity 269, 270
femoral hernia
borders that define the femoral ring 404
comparison with inguinal hernia 404
repair 404
repair options for incarcerated hernia 406–407
femoral vein injury, options for repair 332
fentanyl
mechanism of action 122
postoperative pain management 98
fingers, replantation of traumatic amputations 323
flail chest
cause and management 300
causes of hypoxia related to 300
risk factors and management 450–451
flexible bronchoscopy, diagnostic and therapeutic indications 258
fluconazole, use in central nervous system infections 53–54
fluid and electrolytes 135–144
fluid movement across capillary membranes 14
fluid resuscitation, role of lactate clearance in the critically-ill patient 65–66
flumazenil, mechanism of action 101–102
fondaparinux, use in DVT prophylaxis 202–203
Fournier’s gangrene, management 341
Frank–Starling law of the heart 4
free air in the chest and abdomen, cause in steroid-treated trauma patient 149
fulminant liver failure
clinical features and mortality risk 173–174
treatment of acetaminophen poisoning 175
functional capacity, pre-surgery assessment 75
fungus infection in transplant patients, antifungal treatment 211
furosemide, effects in acute kidney injury (AKI) 164–165
futile care, issues related to continuation 496
gallbladder 385–392
cancer diagnosis and management 390
gallbladder polyps, classification and management 389–390
gallstone disease, management during pregnancy 389
gallstone ileus, clinical presentation and management 388–389
gallstones
management of asymptomatic gallstones 385–386
risk factors for developing 387
gamma-aminobutyric acid (GABA), role in alcohol withdrawal pathophysiology 132
gastric band patient
cause of poor PO tolerance 419
removal of band fluid 419
signs and symptoms of gastric band erosion 418
treatment of gastric band erosion 418–419
gastric band port site infection, cause of 418
gastric bypass
anastomotic leak detection and treatment 368–369
see also Roux-en-Y gastric bypass
gastric decontamination procedure for drug overdose 241
gastric Dieulafoy’s lesion, diagnosis and management 368
gastric dysmotility, effects in pediatric critical care patients 232
gastric outlet obstruction, management of malignant obstruction 364
Geneva Conventions 492
Geneva Score (revised) for PE diagnosis 204
gentamicin, interaction with neuromuscular blocking agents 70–71
geriatrics 465–475
Glasgow Coma Score
determination for all injured
patients 276–277, 277
prediction of poor outcome in
penetrating brain injury
191–192
 glutamate, role in alcohol withdrawal
pathophysiology 132
 glutamine
requirements in trauma and critical
care patients 178
role in nutritional support for
critically‐ill patients 178
goal‐directed echocardiography
(GDE) examination, standard
views 261–262
graduated compression stockings
(GCSs), effectiveness for
DVT prophylaxis
199–200
granisetron, antiemetic action 99
Graves’ disease, postoperative thyroid
storm 148
Greenfield filter, long‐term follow‐up
of patients 207–208
groin hernia, surgical evaluation for
repair 403
Guillain–Barré syndrome, diagnosis
and therapy 197
gunshot wounds
brain injury 191–192
control of pulmonary
hemorrhage 444
detection and treatment of ureteral
injury 341–342, 342
factors which help limb
salvage 335, 335
indications of underlying vascular
injury 327
management of esophageal injuries
364–365
management of major vascular and
musculoskeletal injuries
335, 335
management of multiple
penetrating injuries and
bleeding 338–339, 339
pediatric penetrating thoracic
trauma 458
predictor of poor outcome in brain
injury 191–192
revascularization of injuries
335, 335
treatment of intraperitoneal colon
injury 375
type of vascular injuries from
shotgun wounds 334–335
use of intravascular shunting
335, 335
gynecologic surgery 431–437
h
Haemophilus influenzae, association
with VAP 96
Hagen‐Poiseuille equation 3
haloperidol, side‐effects 131
halothane, potential side effects 124
hand trauma 317–325
hanging (non‐lethal), common
presenting injuries 291
head trauma, indications for CT scan
in pediatric patients 463–464
heart, age‐related changes 465
heat exchange, types of 153
heat exhaustion, definition 154–155
heat loss from the body,
mechanisms 153
heat‐related illness, medications
which increase the risk of
156–157
heat stroke, definition 154–155
Helicobacter pylori infection
increasing prevalence with age 470
methods of testing for 367–368
HELLP syndrome, distinction from
acute fatty liver of pregnancy
(AFLP) 470
hemodynamic monitoring 59–67
hemolytic uremic syndrome (HUS),
pregnant patient 222–223
hemoperitoneum, diagnosis and
treatment 118
hemophilia, excessive bleeding after
trauma or surgery 115
hemoptysis, management of massive
hemoptysis 443–444
hemorrhage
activation of massive transfusion
protocol 329, 455–456
indications for REBOA 314
management of pulsatile
hemorrhage from deep stab
wounds 329
pediatric trauma patients requiring
massive transfusion 455–456
use of tourniquet to control
328–329
hemorrhagic shock, diagnosis and
treatment 21
hemorrhoids
conditions referred to as
381–382
diagnosis and management
381–382
hemostasis 109–119
“lethal triad” of coagulopathy,
acidosis, and
hypothermia 117
hemoperitoneum diagnosis and
treatment 118
use of rapid thromboelastography
(TEG) in trauma patients
112, 112
use of tranexamic acid (TXA) in
trauma patients 110–111
hemothorax, post‐traumatic retained
hemothorax 446
heparin anticoagulation 99–100
heparin‐induced thrombocytopenia
(HIT)
diagnosis and management
100–101, 115–116
treatment when platelet count
normalizes 101
hepatic artery thrombosis (HAT),
diagnosis in liver transplant
patients 217
hepatic blush on CT, pediatric blunt
abdominal trauma
patients 231
hepatic dysfunction, choice of
neuromuscular blocking
agent 97, 98
hepatic encephalopathy,
pathophysiology and
treatment 171–172
hepaticojejunostomy 385
hepatolithiasis, diagnosis and
management 390
hepatopulmonary syndrome,
diagnosis 175–176
hepatorenal syndrome
distinction from prerenal
azotemia 209
pathogenesis 170–171
hepatotoxicity, features of acute
acetaminophen intoxication
174–175
hernias 403–407
repair using the component
separation technique 405
heroin users, effects of use of Krokodil alternative to heroin 248–250
hiatal hernia
symptoms and management 366
types of 366
high-frequency oscillation ventilation, parenchymal-pleural fistula (PPF) management 82
hip dislocation, diagnosis and management 324
HIV testing of patients 498
transmission risk for healthcare workers 498
HIV/AIDS patients, opportunistic infections 93
Hofmann elimination process 97, 98
hospital-acquired infections, catheter-related bloodstream infections (CRBSI) 62, 63
hospital antibiograms, use in choice of antibiotic therapy for VAP 104
hydatid disease of the liver, cause and treatment 394
hydromorphone, postoperative pain management 97–98
hyperacute rejection, symptoms and management 213–214
hyperbaric oxygen (HBO) therapy, use as adjunctive treatment for NSTIs 413
hypercalcemia
definition and etiologies 140
symptoms and treatment 140
hyperglycemic hyperosmolar state (HHS), diagnosis and treatment 150–151
hyperkalemia
diagnosis and treatment 139
etiologies 139
indications for dialysis 161–162
prevention of malignant ventricular arrhythmias 164
risk associated with succinylcholine 137
signs and symptoms of stage 3 AKI 163
hypertension
appropriate choice of medication 147
preoperative medications to control 147–148
treatment during pregnancy 38 221–222
hypertensive emergencies 33–50
hyperthermia 153–157
effect of fever in brain injury 156
risk related to age 153
hypalbuninemia, anion gap in ICU patients 143
hypocalcemia
presentation 141
risk after parathyroidectomy 145
with hypomagnesemia 141
hypocortisolism, signs and symptoms 146–147
hypoglycemia, from overdose of a hypoglycemic agent 244–245
hypomagnesemia
association with digitalis toxicity 138, 138
symptoms 16
with hypocalcemia 141
hypoponatemria
causes and treatment 136
diagnosis and pathophysiology in cirrhosis 176
management of acute hypoponatemria 139
symptoms of acute hypoponatemria 139
treatment in edematous patients 136–137
hypophosphatemia, pathophysiology in critically-ill patients 141–142
hypotension in trauma patients
causes in intubated sedated patient 124–125
causes in trauma patients 293
indications for REBOA 314
intervention to maximize oxygen delivery (DO2) 6
treatment for persistent hypotension in the ICU patient 137
hypothalamic-pituitary-adrenal (HPA) axis 148
hypothermia 153–157
cardiovascular and hemodynamic effects 156
changes in core body temperature 154
“lethal triad” of coagulopathy, acidosis, and hypothermia 117
metabolic consequences 157
perioperative risk and consequences 155–156
rewarming method and rate 154
role in mortality of trauma patients 117
role in perioperative complications 126
signs and symptoms 154
therapeutic 155, 157
hypotonic hypoponatemria, causes and treatment 136
hypovolemic shock
diagnosis and treatment 21
hypotension caused by 293
oxygen extraction (O2ER) calculation 19
ways to promote end-organ profusion 4–5
hypoxemia, etiologies 10–11
ICU, common procedures 253–260
idarucizumab, reversal agent for dabigatran 118–119, 118
ideal body weight (IBW) calculation 416
idiopathic thrombocytopenic purpura (ITP), management 398–399
iliac vein injuries, factors affecting mortality and morbidity 310–311
imaging in pediatric patients, ways to reduce the total dose of radiation 464
immune-enhancing formulas
effects in critically-ill patients 184, 185
role of nucleotides 185
immune-suppressed patients, combination antibiotic therapy 92–93
immunology 209–217
immunonutrition
effects in critically-ill patients 185
recommendations for ARDS patients 183–184
immunosuppression in transplant patients 209–210, 210
incarcerated hernias 403–407
para-colostomy hernia small bowel obstruction 406, 406
repair options for femoral hernia 406–407
umbilical hernia in patient with cirrhosis 381
incidence, definition 486
incisional hernia, principles for repair 405
infectious disease 89–96
Infectious Disease Society of America (IDSA), guidelines for management of VAP 104–105, 104
inferior vena cava (IVC) filter indications for 255–256
management of a damaged filter 207–208
potential complications 255–256
inflammatory response to injury 51–58
informed consent for participation in research studies 488
in emergency situations 495
issues in end-of-life care 495
patient refusal of treatment 469–470
inguinal hernia, comparison with femoral hernia 404
inhaled burn injury, treatment 428
injury and stress, phases of response to 177
inotropic support, mechanism of action of dobutamine 62
insulin therapy, multiply-injured trauma patient 146
insurance companies, correction of incorrect claims 499
intermittent pneumatic compression devices (IPCs), effectiveness for DVT prophylaxis 199–200
interquartile range (IQR) 484
interventional radiology 261–272
intimate partner violence (IPV), risk factors and consequences in pregnancy 435
intra-abdominal HTN, assessment for 81
intra-abdominal hypertension, definition and risk factors 314–315
intra-abdominal insufflation, physiologic changes caused by 76
intra-abdominal pressure measurement, using bladder pressure 81
intra-aortic balloon pump (IABP) complications 440–441
indications, placement, and physiology 11–12
intracranial hemorrhage, in anticoagulated elderly patients 466–467
intracranial hypertension, common causes 189
intracranial pressure (ICP) decompressive craniotomy 197–198
DECK trial (2011) findings 197–198
decreasing ICP without lowering BP 284
management of elevated ICP 190
management of elevated ICP in pediatric trauma patients 196–197
optimizing in traumatic brain injury 283–284
RESCEUEicp trial (2016) findings 197–198
surgical management of uncontrollable elevation 197–198
therapy for increased ICP in traumatic brain injury 280–281
use of mannitol for osmotic therapy to reduce 190–191
intracranial pressure (ICP) monitoring devices used for 193–194
objective in traumatic brain injury 189–190
severe traumatic brain injury patients 279
intraparenchymal cerebral hematoma, indications for immediate surgery 190
intravascular catheter-related infection, prevention practices 94
intravascular volume status, indications from stroke volume variability (SVV) 60
intravenous immunoglobulin (IVIG) treatment of NSTIs 412
treatment of refractory C. difficile infection 100
intubation identifying unrecognised misplaced intubation (UMI) 64–65
Mallampati classification 69, 70, 70
modalities to improve success rate in Mallampati IV airway 69–70
prediction of difficult intubation 69, 70, 70
invasive candidiasis empiric antifungal therapy 106
risk factors for 106
invasive zygomycosis, initial treatment 414
ischemia reperfusion lung injury (IRLI), following lung transplant 215
ischemic colitis diagnosis and management 380–381
isoflurane, metabolism 124
Jefferson fracture 295, 295
Jehovah’s Witness patient, management of splenic injury 401
Jehovah’s Witnesses, refusal of blood transfusion for a child 499
Kaplan–Meier survival curve 488–489, 489
Kcentra (PCC), use for rapid reversal of anticoagulation 114
ketamine amnestic and analgesic effects 127–128
dissociative anesthetic 127–128
use in rapid-sequence intubation 72–73
ketorolac, mechanism of action 122
Klebsiella species antibiotic resistance in K. pneumoniae 95–96
association with CRBSI 63
association with VAP 96
knee dislocation
management of high-energy dislocation 322–323
management of low-energy dislocation 323
popliteal artery injury associated with 331–332
Krokodil (Crocodile, Krok, Croc), effects of use as alternative to heroin 248–250
Kruskal-Wallis test 485

laboratory risk indicator for necrotizing fasciitis (LRINEC) score 341, 411, 411
lactic acid, role of lactate clearance in successful fluid resuscitation 65–66
laparoscopic cholecystectomy 385
early versus delayed procedure 386
laparoscopy, physiologic changes caused by intra-abdominal insufflation 76
Law of LaPlace 5
left anterior fascicular block (LAFB), EKG deviation 37–38
left ventricular pseudoaneurysm 38–39, 38
Legionella pneumophila infection 55
lidocaine 15–16
effects of addition of epinephrine 72
mechanism of action 72
life-saving therapy, patient refusal of 491
lightning strike victims
initial concerns and management 428–429
most common cause of death 429
neurologic sequelae 429
linezolid, use in VAP 104–105
lipid administration in critically-ill patients 182
lisinopril, mechanism of action 147
lithium overdose, toxic effects and treatment 242–243
liver 393–398
anatomy 396–397, 396
liver abscess, pyogenic and amebic types 393
liver cirrhosis
diagnosis of hepatopulmonary syndrome 175–176
effect on morbidity and mortality in trauma patients 395–396
fluid leakage from umbilical hernia 404–405
hyponatremia diagnosis and pathophysiology 176
management of esophageal varices 170
management of hepatic encephalopathy 171–172
management of intractable ascites 173
management of persistent bleeding 173
management of pulmonary embolism 210–211
management of upper gastrointestinal bleeding 170
prognostic models for surgical patients 169, 170
risk of increased morbidity and mortality after surgery 397–398, 397
symptoms and treatment of Vibrio vulnificus infection 211–212
liver cirrhosis and ascites, incarcerated/strangulated umbilical hernia 381
liver disease, pathogenesis of hepatorenal syndrome 170–171
liver failure 169–176
clinical features and mortality risk 173–174
distinction between prerenal azotemia and hepatorenal syndrome 209
nutritional therapy 187
treatment of acetaminophen poisoning 175
liver injury
abdominal computed tomography (CT) 393–394, 394
APSA guidelines for pediatric blunt trauma 234–235, 234
bile leak following laparotomy and hepatorraphy 309
blush on CT scan 308
criteria for nonoperative management 307
delayed complications 395
indications for angiography and possible embolization 308
nonoperative management 393–394, 394
post-injury biloma complication 394–395
post-injury hemobilia 395
liver transplantation
diagnosis of hepatic artery thrombosis (HAT) 217
indications and contraindications 214
indications and outcomes 173–174
use of calcineurin inhibitors 210
liver trauma
management of blunt trauma 393
nonoperative management 393
liver tumors
classification as benign or malignant 397, 397
types of 397, 397
local anesthetics
amino ester and amino amide types 126
early clinical signs of central nervous system toxicity 125
ester and amide types 72
mechanism of action 71–72
lorazepam, mechanism of action 101–102
low-molecular-weight heparin (LMWH) anticoagulation 99–100
epidural analgesia and 204
prophylactic use 203
lower extremity ulceration, illicit drug likely to cause 248–250
lower gastrointestinal bleeding, management 375–376
LRINEC score 341, 411, 411
lumbar puncture complications 260
use in the ICU 260
lung resection, acute bronchopleural fistula (BPF) complication 441
lung transplantation
causes of postoperative pneumonia 216
etiology of respiratory failure 215
risk of ischemia reperfusion lung injury (IRLI) 215
lungs, West lung zones 12
mafenide acetate antimicrobial, side effects 427–428
magnesium sulfate 15
malignant gastric outlet obstruction, management 364
malignant hyperthermia (MH) causes, symptoms, and treatment 77–78
indicators of 126
malignant ventricular arrhythmias, prevention in severe hyperkalemia 164
Mallampati classification 69, 70, 70
Mallory-Weiss tear, definition and management 361
mannitol, use in osmotic therapy to reduce intracranial pressure 190–191
Mann-Whitney U test 487
massive transfusion blood component therapy 109
definition 111–112
electrolyte abnormalities associated with 113–114
hypocalcemia associated with 113–114
plasma for patient of unknown blood type 112–113
ratio and type of platelets 113
massive transfusion protocol (MTP) 329
activation criteria 111–112
for pediatric patients 455–456
McNemar’s test 485
MDMA (Ecstasy/Bath salts), mechanism of action 250–251
mean (measure of central tendency) 484
mechanical ventilation see ventilator support
Meckel’s diverticulum, diagnosis and management 377, 377
median (measure of central tendency) 484
mediastinitis, postoperative initial management 89
microorganism associated with 89
medical errors, disclosure and liability 497–498
medical insurance, correction of incorrect claims 499
medical malpractice, liability issues in compartment syndrome 321–322
medical professionalism 495–496
medical research, justification for performing 493
medications, effect on risk of heat-related illness 156–157
melena, presenting sign of PUD in elderly patients 470
meperidine mechanism of action 122
postoperative pain management 98
meropenem, antimicrobial action 105
mesenteric ischemia (NOMI), identification and management 474–475
mesenteric venous ischemia associated with thrombosis 380, 380
metabolic acidosis anion gap type 141, 143
effect of albumin on anion-gap type 143
diagnosis and assessment 137
indications for use of sodium bicarbonate 167
non-anion gap type 140, 141
metabolic alkalosis, causes 136
metabolic equivalents (METS) measure of functional capacity 75
metabolic illness 145–151
metabolism, effects of aging 472
methanol ingestion, toxicity and treatment 243
methemoglobinemia diagnosis and treatment 139–140
drugs associated with 140
etiologies and treatment 123–124
methylprednisolone-resistant Staphylococcus aureus (MRSA) see MRSA
methylprednisolone-susceptible Staphylococcus aureus (MSSA) 89, 96
metoclopramide, antiemetic action 99
metoprolol overdose, symptoms and management 247
metronidazole, use in VAP 104–105
micronutrients, supplementation in critically-ill patients 182–183
midazolam hemodynamic side effects 72–73
mechanism of action 101–102, 128
Model for End-stage Liver Disease (MELD) risk scoring system 169, 170
moral judgment, prima facie concept 492–493
Moraxella species, association with VAP 96
morphine mechanism of action 122
postoperative pain management 97–98
motor bike accident trauma patient, evaluation and management 281–282
MRCP (magnetic resonance cholangiopancreatography), preoperative detection of common bile duct stones 266–267
MRSA (methicillin-resistant Staphylococcus aureus) association with VAP 55, 96
risk factors for VAP 104–105, 104
MRSA soft tissue infections, predictor of treatment failure and hospital mortality 410
MSSA (methicillin-susceptible Staphylococcus aureus) 89, 96
multidrug resistant (MDR) pathogens, risk factors in VAP 104–105, 104
multidrug resistant (MDR) pneumonia, risk factors for 96
multifocal atrial tachycardia (MAT), ECG trace and treatment 80
multi-organ dysfunction syndrome (MODS), definition 51
multivariable analyses 484
multivariable linear regression 487
multivariable logistic regression 487
munificence 491
muscle protein catabolism in critically-ill and injured patients 179
Mycoplasma infection 55
myelinolysis 139
myocardial infarction (MI) complications 40–41, 40
complications after 48–49 perioperative preventive medication 73
right-sided ventricular infarction 45–48, 46, 47
ventricular fibrillation following 49–50, 49
myocardial oxygen consumption (MVO2), factors influencing 5
myonecrosis, most common cause 411–412
myxedema coma, diagnosis and treatment 151
near infrared spectroscopy (NIRS) monitoring of pediatric critical care patients 228
tissue oxygenation assessment 228
neck vascular anatomy 287, 288
zones of the neck 287, 288
neck trauma 287–297
anterior Zone II stab wound 289–290
blunt cerebrovascular injury (BCVI) 288–289, 289, 289, 289
“clothesline” injury management 297
indications for BCVI screening 290
operative versus non-operative management 287, 288
repair of esophageal laceration 292
repair of tracheal laceration 292
seatbelt sign 288–289, 289, 289, 289, 289, 289
tracheal injury 289–290
Zone II penetrating trauma management 287–288, 294
necrotizing fasciitis cervical necrotizing fasciitis 413–414
choice of antibiotic 106–107
laboratory risk indicator (LRNEC) score 411, 411
most common cause 411–412
necrotizing pancreatitis antibiotic prophylaxis 392
diagnosis and treatment approaches 390–391
necrotizing soft tissue infections (NSTIs) 409–414
antibiotic choice 106–107
antibiotic regimen 95
causative organisms 94–95
classification 95, 412
diagnosis 409–410, 410
infection 412
hard signs 409, 410
hyperbaric oxygen (HBO) therapy 413
IVIG therapy 412
microbiologic etiologies 412
negative-pressure wound therapy (NPWT) 412
perineal region signs 94–95
negative pressure pulmonary edema, following extubation 79–80
negative-pressure wound therapy (NPWT), use in NSTI management 412
neostigmine, action as NMBA reversal agent 107, 108
neurogenic diabetes insipidus, diagnosis 145
neurocritical care 189–198
neurogenic shock diagnosis, etiology and treatment 21
hypotension caused by 293
neuromuscular blocking agents (NMBAs) causes of continued paralysis 70–71
choice for burn victims 122
choice in patients with hepatic and/or renal dysfunction 97, 98
choice of appropriate agent 72
effects of inadequate reversal 79
for critically-ill patients with liver or renal disease 122–123
interaction with aminoglycoside antibiotics 70–71
methods of elimination 97, 98
patient with a contraindication to succinylcholine 123
reversal agents 107
risk factors for inadequate reversal 79
neuropenic enterocolitis, complication of chemotherapy 374–375
Nimbex see cisatracurium
nitric oxide (NO), role in vasodilation 57–58
nitroprusside, cyanide toxicity associated with 247–248
nitrouric acid, risks for patients with vitamin B12 deficiency 124
non-accidental trauma in children blunt abdominal trauma 235
reporting suspicious cases 458
non-ethanol alcohols, toxicity and treatment 243
non-invasive positive pressure ventilation (NIPPV) contraindications 86
method and uses 86
non-invasive ventilation (NIV), effects in the immediate postoperative setting 79
nonmaleficence 491, 493
nonmalfeasance 491
non-occlusive mesenteric ischemia (NOMI), identification and management 474–475
non-parametric (asymmetric, skewed) distribution 484, 484
non-parametric tests of significance 485
nonrational requests from patient’s family 495
nonrational thinking 491
normal (parametric) distribution 484, 484
normal saline (0.9% NaCl solution), effect on plasma volume 144
nosocomial infections, common pathogens 105–106
nutrition functions of 185
role in immunonutrition 185
null hypothesis, criteria for rejection 485–486
nutrients, location of absorption within the GI tract 419–420
nutrition effects of ageing 472
requirements of children compared to adults 459
nutritional support deficiencies after bariatric surgery 419, 420
Index

for critically-ill elderly patients 471–472
in acute kidney injury (AKI) 471–472
in critically-ill patients 177–188
preferred routes 77
refeeding syndrome (RFS) 77
requirement of burn patients 427
nutritional therapy
burn patients 188
in hepatic failure 187
in pulmonary failure 186–187
obese critically-ill patients 188
severe pancreatitis 187–188

O
obese patients 415–422
body mass index (BMI) classification 415, 416
effects of obesity on pulmonary physiology 415
increase in prevalence of obesity 415
nutritional therapy for critically-ill patients 188
recommendation for bariatric surgery 415
risks from obstructive sleep apnea (OSA) 416–417
tracheostomy complication rates 416
ventilator tidal volume setting 416
obstetric critical care 219–226
obstructive sleep apnea (OSA), risk in obese patients 416–417
odds ratio 487–488
Ogilvie’s syndrome 374
ondansetron, antiemetic action 99
open fractures
choice of antibiotic prophylaxis 321
duration of intravenous cefazolin administration 320
infection risk 319–320, 319
timing of debridement in trauma patients 320
organ donation
avoiding the appearance of conflict of interest 497
issue of continuation of futile care 496
obtaining consent for 492, 497
separation of the treatment and organ transplant teams 497
orthopedic trauma 317–325
ovary, pseudomyxoma peritonei symptoms and treatment 373
overdose patient
gastric decontamination procedure 241
use of whole bowel irrigation (WBI) to prevent drug absorption 239
overwhelming postsplenectomy infection (OPSI), risk of 401–402
oxycodeone, postoperative pain management 98
oxygen content (CaO2) of blood, calculation 18
oxygen delivery (DO2) 15–21 calculation 18, 65
definition 65
intervention to maximize in refractory hypotension 6
optimizing in the critically-ill patient 65
oxygen delivery index (DO2I), calculation 65
oxygen-dissociation curve, factors which shift the curve to the right or left 19
oxygen extraction (O2ER) calculation 19
oxygen saturation (SpO2), methods of measurement 59–60
oxygen uptake/consumption (VO2) calculation 18

P
p-values 485
relationship to 95% confidence intervals (CIs) 486
packed red blood cell (PRBC) transfusion
effects of liberal transfusion 111
pediatric critically-ill patients 228–229
pain management, analgesics for postoperative pain 97–98
see also analgesia
paired Student’s t-test 487
pancreas 385–392
pancreas transplantation, effects on complications of diabetes 217
pancreatic injuries
AAST classification 391
caused by blunt trauma 310
evaluation and management 391
management challenges 391–392
management of blunt trauma in children 461–462, 461, 461
pancreatitis
acute flare-up 141
antibiotic prophylaxis 392
optimal nutritional support 386–387
pancrumonium
mechanism of action 122, 123
metabolism and elimination 72, 97, 98
reversal drugs 107
papillary muscle rupture 40–41, 40
para-colostomy hernia
incarcerated hernia with small bowel obstruction 406, 406
incidence and risk factors 405–406
paraesophageal hernia
symptoms and management 366
types of 366
parametric (normal) distribution 484, 484
parametric tests of significance 485
parastomal hernia, incidence and risk factors 405–406
parathyroidectomy, postoperative hypocalcemia risk 145
parenchymal-pleural fistula (PPF) management 82
parenteral nutrition, in severe burn patients 427
patient autonomy 491
PCP, mechanism of action 250–251
peak airway pressures
high pressures in a postoperative patient 83–84
pressure versus volume tracing assessment 83–84
significance of rising pressures 81
Pearson’s correlation coefficient 487–488
Pearson’s Χ2 test 487–488
pediatric acute respiratory distress syndrome (PARDS)
anticillary treatment 230–231
definition 229, 229
titrating mechanical ventilatory support 230
ventilation support recommendations 229–230
penetrating torso trauma, use of triple contrast CT scans 267–268
penicillin-allergic patient, antibiotic choices 414
peptic ulcer disease (PUD) causes 362–363
presentation in elderly patients 470
management of bleeding from ulcers 362–363
percutaneous coronary intervention (PCI), effect on subsequent non-cardiac surgery 75
percutaneous endoscopic gastrostomy (PEG) tube considerations for tube placement 259
esophageal perforation 449, 449
perianal hematoma, diagnosis and management 381–382
pericardial effusion, assessment via transthoracic echocardiography (TTE) 261
pericavicular gunshot wound, evaluation 302–303
perilunate dislocation, avoiding delay in diagnosis and management 325
perineum, management of penetrating traumatic injury 382
perioperative hypothermia definition, consequences, and prevention 155–156
role in perioperative complications 126
perioperative management 69–78
peripartum cardiomyopathy, diagnosis and management 220
peripheral arterial injury management 329
use of a temporary intravascular shunt (TIVS) 329–330
peripheral vascular injury benefits of completion angiography after repair 330–331, 331
factors affecting survival 330–331, 331
peripheral vascular resistance (PVR), calculation 67
peripheral vascular trauma diagnostic testing 328
indication for a therapeutic decompressive fasciotomy 333
pharmacodynamics alterations in critically-ill patients 102–103
definition 103
pharmacokinetics alterations in critically-ill patients 102–103
definition 103
phenothiazines, antiemetic action and side effects 99
pheochromocytoma, symptoms, incidence, and management 147–148
phlebostatic axis, definition 66
physical status, American Society of Anesthesiologists (ASA) classification 71
physician incompetence, action required 494
physician self-referral, ethical and legal issues 496–497
piperacillin/tazobactam, antimicrobial activity 105–106
placental abruption, diagnosis and management 219
Plasma-Lyte resuscitation fluid, properties 142
platelet inhibitor therapy, perioperative management 116–117
Plavix 44
pluralism 493
pneumonectomy, acute bronchopleural fistula (BPF) complication 441
pneumonia causes in lung transplant patients 216
risk factors in trauma patients 94
pneumothorax diagnosis and management 447
signs of 80
poisonings 239–251
AACT/EAPCCT guidelines for management 243
polyene antibiotic family, mechanism of action 102
polymorphic ventricular tachycardia 41–42, 41–42
popliteal artery injuries associated with knee dislocation 331–332
evaluation and management 331–332
rate of limb salvage 331–332
portal-systemic encephalopathy, pathophysiology and treatment 171–172
positive end-expiratory pressure (PEEP)
effect in a severely hypoxic patient with ARDS 6
effect in patients who have ARDS 9
optimal location on a volume-pressure curve 13
positive pressure ventilation, effects on cardiac function 5–6
postdural puncture headache, symptoms and treatment 125–126
postoperative acute respiratory failure, most likely cause 79
postoperative Candida glabrata infection, antifungal treatment 96
postoperative candidiasis, antibiotic prophylaxis 93
postoperative Clostridium difficile infection, management 89–90
postoperative mediastinitis initial management 89
microorganism associated with 89
postoperative mortality, medications likely to decrease mortality risk 93
postoperative myocardial infarction, preventive medication 73
postoperative nausea and vomiting, antiemetics 99
postoperative oliguria, initial workup 160–161
postoperative pain management, choice of analgesic 97–98
postpartum patient causes of hypotension, hypoxemia, and/or hemorrhage 434–435
endometriosis diagnosis and treatment 225
risk of VTE 201–202
postpartum septic pelvic thrombophlebitis, diagnosis and management 223–224
post-thrombotic syndrome (PTS), pathophysiology and management 200
power of a study sample 483–484
Pradaxa see dabigatran
prealbumin, function as a negative acute phase protein 178–179
Precedex see dexmedetomidine
pregnancy cardiovascular changes during management of choleodocholithiasis 389
management of gallstone disease 389
respiratory and metabolic changes 221
risk of VTE 201–202
safe antihypertensive medications 38
pregnant patient 345–357
airway management 355
cardiocographic monitoring after blunt trauma 345
causes of hypotension, hypoxemia, and/or hemorrhage 434–435
characteristics of VTE in pregnancy 223
CPR and emergent Cesarian section 436–437
diagnosis and treatment of pulmonary embolism 224–225
differential diagnosis for altered mental state (AMS) 352
fetal risk of critical care medications 222
fetal survival in maternal cardiac arrest 437
guidelines for laparoscopic appendectomy 434
hemolytic uremic syndrome (HUS) 222–223
hypercoagulability of pregnancy 349–350
imaging radiation exposure concerns 348–349
imaging risks and considerations 267
incidence and types of trauma in pregnancy 356
indications for emergency Cesarean section 349
initial assessment and treatment of trauma patients 436
management changes in initial evaluation and resuscitation 353
management of neurologic injury 348
mortality rate for trauma during pregnancy 356
normal laboratory studies in pregnancy 355–356
perimortem emergency C-section procedure 351–352
physiological changes associated with pregnancy 346–347
posterior reversible encephalopathy syndrome (PRES) 225
presentation and diagnosis of acute appendicitis 433
risk and consequences of intimate partner violence (IPV) 435
risk of intimate partner violence 351
risk of placental abruption and fetal demise 353–354
risk of thromboembolism in pregnancy 349–350
routine assessment of fetal well-being 354–355
seat belt use by pregnant women 350–351
thrombotic thrombocytopenic purpura (TTP) 222–223
tocolytic associated pulmonary edema 226
tocolytic medications to prevent premature labor 345–346
treatment of acute appendicitis 433–434
treatment of HELLP syndrome 352–353
treatment of scald burn injuries 436
use and interpretation of the Kleihauer-Betke test 347–348
uterine rupture caused by trauma 356–357
pre-renal azotemia distinction from acute tubular necrosis 160
distinction from hepatorenal syndrome (HRS) 209
pressure-volume dysregulation, “bird’s beak” phenomenon 88, 88
preterm labor, tocolytic-associated pulmonary edema 226
prevalence, definition 486
prima facie nature of principles and moral rules 492–493
principlism 491, 495
prisoners of war (POWs), ethical and humane treatment by physicians 492
prochlorperazine, antiemetic action and side effects 99
professional conduct in patient care 495–496
progesterone, use in traumatic brain injury treatment 196
prognostic models, for surgical patient with liver cirrhosis 169, 170
prolonged QT interval 42, 42
propofol common side effects 121
hemodynamic side effects 72–73
mechanism of action 121, 128
metabolism 124
propofol infusion syndrome 125
protein synthesis in critically ill and injured patients 179
process of mRNA translation 179–180
sites of 179–180
prothrombin complex concentrate (PCC) for rapid reversal of anticoagulation 114, 118–119
use to normalize INR 61–62
protocolized emergency department sepsis guideline 227
Pseudomonas aeruginosa antibiotic resistance 95–96
association with VAP 55, 96
beta-lactamase production 105–106
choice of antimicrobial medication 105–106
duration of antibiotic therapy for VAP 90
risk factors for MDR Pseudomonas VAP 104–105, 104
use of combination antibiotic therapy 92–93
pseudomyxoma peritonei, symptoms and treatment 373
psychiatric disorders 129–134
psychosis etiologies 134
psychosis presentations and management 133–134
pulmonary artery catheter (PAC) false cardiac output measurement caused by cardiac abnormalities 62–63
indications and contraindications for placement 63–64, 254–255
information provided by 254–255
pressure changes as the catheter is being placed 61–62
thermodilution principle 62–63
pulmonary edema following myocardial infarction 40–41, 40
in ALI/ARDS 14
re-expansion pulmonary edema 445
tocoletic-associated pulmonary edema 226
pulmonary embolism (PE)
AAOS recommendations for prophylaxis 205–206, 206
diagnosis and treatment in a pregnant patient 224–225
diagnostic scoring systems 204
diagnostic use of D-dimer 203–204
enoxaparin administration 99–100
following bariatric surgery 420
following spleen injury 199
incidence and management 202–203
inferior vena cava (IVC) filter placement 255–256
management in patients with cirrhosis 210–211
prophylaxis for total knee or hip replacement 205–206, 206
treatment of acute PE 439–440, 440
pulmonary failure, nutritional therapy 186–187
pulmonary physiology, effects of obesity 415
pulmonary trauma, control of pulmonary hemorrhage 444
pulse oximetry monitors, factors affecting the accuracy of readings 59–60
pulsaless electrical activity (PEA) arrest 15, 16
pulsus paradoxus, definition and etiologies 20–21
qu
quinupristin/dalfopristin, antimicrobial action 104
r
radiocontrast media, contrast-induced nephropathy (CIN) 76
radius, nerve injury in distal radius fractures 324–325
randomization of subjects in a study 488
rapid-sequence intubation choice of neuromuscular blocker 122
drugs used for head-injured trauma patients 72–73
rapid shallow breathing index (RSBI) 64, 86
REBOA (resuscitative endovascular balloon occlusion of the aorta), indications and contraindications in trauma patients 306, 314
rectal bleeding colon tumor management 376
ischemic colitis diagnosis and management 380–381
rectal foreign bodies, removal 383
rectal prolapse, assessment and management 378–379, 378
rectum 371–383
management of extraperitoneal penetrating trauma 382
re-expansion pulmonary edema, diagnosis and management 445
following drainage of pulmonary effusion 445
refeeding syndrome (RFS), biochemical derangement in 77
relative risk 487–488
renal dysfunction choice of neuromuscular blocking agent 97, 98
risk in elderly trauma patients 468–469
renal injuries incidence and management in trauma patients 309–310
pediatric blunt kidney trauma 235
penetrating renal injury 342–343, 343
renal exploration for trauma 342–343, 343
Index

renal replacement therapy
advantages over intermittent
dialysis 165–166
in elderly patients 468–469
renal transplant patients
common causes of late
deaths 212
diagnosis of calcineurin toxicity
209–210, 210
diagnosis of renal artery
thrombosis 214
drug-drug interactions
209–210, 210
post-transplant
complications 214
side effects of thymoglobulin
induction agent 216–217
treatment for invasive fungal
infection 211
renin-angiotensin-aldosterone
system 147
RESCUEicp trial (2016) findings
197–198
research, justification for
performing 493
RESP score 25–26, 25
respect (ethical principle) 491
respiratory acidosis
adjustment of ventilator
settings 84
diagnosis and treatment 142–143
respiratory failure management, role
of ECMO 87
respiratory monitoring 59–67
respiratory physiology 3–14
resuscitation
for hemoperitoneum 118
management of continued
hypoperfusion 91
resuscitation fluids
edema promotion effects
143–144
effect of normal saline on plasma
volume 144
normal saline and Plasma-Lyte
compared 142
resuscitative thoracotomy, indications
for 304–305
retained hemothorax
diagnosis and management 446
treatment following blunt chest
trauma 306
retinol-binding protein, function as a
negative acute phase protein
178–179
retroperitoneal hematomas,
indications for surgical
exploration 311–312, 311
retroperitoneal rectal injury,
management 337, 338
rhabdomyolysis, treatment 162
rib fractures
incidence and consequences in
elderly patients 465–466
management in a patient with
COPD 80–81
management of flail chest
450–451
Richmond Agitation and Sedation
Scale (RASS) 127, 127
evaluation of delirium tremens
133, 133
right atrial tracing, analysis
8, 9, 10
right internal jugular dual lumen VV
ECMO catheter,
complications 28–29
right-sided heart failure associated
with severe hypotension,
therapeutic intervention
8, 9
right-sided ventricular infarction
45–48, 46, 47
risk ratio 487–488
rivaroxaban, rapid reversal in trauma
patients 118–119, 118
rocuronium
mechanism of action 122, 123
metabolism and elimination 72, 97, 98
reversal drugs 107–108, 107
Roux-en-Y gastric bypass
anastomotic leak detection and
treatment 368–369
complications 417
diagnosis of a perforated marginal
ulcer 417
diagnosis of acute postoperative
obstruction 421
diagnosis of postoperative enteric
leaks 421–422
internal hernia reduction 421
internal herniation complication
420–421
intraoperative cholecystectomy
417–418
intraoperative treatment of
gallstones 417–418
postoperative nutritional
deficiencies 419, 420
postoperative pulmonary
embolus 420
treatment of a perforated marginal
ulcer 417
salicylate poisoning
toxidrome 241–242
treatment 241–242
sample size for randomized placebo-
controlled blind trials
483–484
scaphoid bone, management of
occult fracture 323
scopolamine, antiemetic
action 99
seat belt mark
association with abdominal
mesenteric injury
379–380, 379
injuries associated with abdominal
seat belt sign 310
second degree heart block (Mobitz
type II) 36–37, 37
sedation
causes and treatment of
hypotension 127
optimum level during mechanical
ventilation 127, 127
propofol infusion syndrome 125
Richmond Agitation and Sedation
Scale (RASS) 127, 127
weaning from 121–122
seizures, following traumatic brain
injury 194
Selective Relaxant Binding Agents
(SRBAs) 107
self-determination principle 491
sepsis 51–58
diagnostic criteria 51
following cystoprostatectomy
339, 339
initial management 51
major cause of vasodilation
57–58
pediatric patient protocolized
emergency department sepsis
guideline 227
resuscitation of pediatric
patients 459
steroid treatment 146
Surviving Sepsis Campaign
recommendations 146
therapeutics which effectively
improve outcomes 56
sepsis-induced inflammatory cascade, role of the coagulation system 57
septic pelvic thrombophlebitis, diagnosis and management 223–224
septic shock
combination antibiotic therapy 92–93
comparison of epinephrine and dopamine treatment in children 231
definition 51
early clinical manifestations 74
indications for the use of corticosteroids 52
Surviving Sepsis Campaign guidelines 231
treatment of “cold” shock indicative of cardiovascular dysfunction 55
treatment of pediatric fluid-refractory septic shock 231
treatment of “warm” or vasodilatory shock 55
use of vasoactive agents 91–92
use of vasopressin 56–57
Serratia species
association with CRBSI 63
association with VAP 96
beta-lactamase production 105
severe pancreatitis, nutritional therapy 187–188
severe sepsis
combination antibiotic therapy 92–93
diagnostic criteria 51
early clinical manifestations 74
initial management 51
sevoflurane, potential side effects 124
Sheehan’s syndrome 148
shock 15–21
early clinical manifestations 74
physiologic changes in various types of shock 59
shock state, relationship between oxygen delivery and oxygen uptake 13–14
shotgun wounds, type of vascular injuries associated with 334–335
sigmoid colon volvulus, recurrent 371–372
silver nitrate antimicrobial, side effects 428
silver sulfadiazine antimicrobial, side effects 428
skin and soft tissue infections (SSTIs) most common identifiable cause 411
predictor of treatment failure and hospital mortality in MRSA SSTIs 410
severe SSTIs caused by diabetic foot infections 413
types of 409
small bowel, mesenteric injury from blunt trauma 379–380, 379
small intestine 371–383
smoking, and cardiac risk 49
snakebite
Crotalinae (pit viper) antivenom administration 245–246
resolution of compartment syndrome caused by 245–246
sodium bicarbonate, indications for use 167
soft tissue infections 409–414
solid organ injuries
management in pediatric patients 463
use of anticoagulation 199
Specific Activity Scale 75
spinal anesthesia, postdural puncture headache 125–126
spinal cord injury (SCI)
complications of complete spinal cord injury 291–292
effects on the reproductive system 291–292
function spared with C7 transaction 279
Jefferson fracture 295, 295
pulmonary function testing 288
use of high-dose steroids 279–280
spinal cord injury without radiographic abnormality (SCIWORA), features in children 454–455
spinal shock
distinction from neural shock 21
presentation 21
spleen 398–402
anatomy 398
spleen injury
angioembolization 400–401
APSA guidelines for pediatric blunt trauma 234–235, 234
contraindication to non-operative management 401
criteria for nonoperative management 308–309
indication for surgical intervention 399–400, 400
Jehovah’s Witness patient 401
management of 199
nonoperative management 263–264
pediatric patients 455, 457–458
presence of a blush on CT scan 399–400, 400
splenic preservation in children 457–458
use of angiography in blunt trauma 263–264
use of anticoagulation 199
splenectomy
following gunshot wound to the spleen 338–339, 339
indications for 401
locations for an accessory spleen 398
overwhelming postsplenectomy infection (OPSI) risk 401–402
predictors of a favorable response 398
vaccinations for splenectomy patients 313
splenic artery aneurysm, diagnosis and management 399
splenic artery embolization, following blunt trauma 263–264
splenic blush on CT, pediatric blunt abdominal trauma patients 231
splenic cyst, classification and management 399
spontaneous bacterial peritonitis, diagnosis and treatment 172
ST-elevation myocardial infarction (STEMI), acute stent thrombosis complication 440
standard deviation (SD) 484
Staphylococcus aureus
association with CRBSI 63
association with NSTIs 94–95
see also MRSA
**Staphylococcus epidermidis**
association with CRBSI 63
treatment of catheter-related bloodstream infection 53
Stark Laws 497
Starling equation 14
statin therapy, use in the perioperative period 73–74
statistics 483–489
stent, patient with effect on subsequent non-cardiac surgery 75
perioperative management of antiplatelet medications 116–117
steroid therapy
use in blunt traumatic brain injury 189
use in sepsis 146
steroid-treated patients interventions to improve wound healing 149–150
symptoms of bowel injury 149
stomach 359–369
stratified randomization 488
streptococcal toxic shock syndrome, choice of antibiotic 107
**Streptococcus pneumoniae**, association with VAP 96
**Streptococcus pyogenes**, association with NSTIs 94–95
stress and injury, phases of response to 177
stress ulcers in high-risk ICU patients, factors associated with increased incidence 74–75
stroke volume, factors determining 4, 4
stroke volume variability (SVV) factors affecting 60
normal range of variation 60
Student’s t-test 485
subarachnoid hemorrhage (SAH), symptoms and management 282–283
subclavian artery injury commonly associated injuries 301–302
concomitant venous injury 301–302
management 302
subdural hematoma causes and management 282
incidence and risk factors 282
subarachnoid hemorrhage, secondary to ruptured cerebral artery aneurysm 192
substituted judgment 491
in end-of-life care 493–494
succinylcholine action as NMBA 107
contraindication for burn victims 122
mechanism of action 122, 123
method of elimination 97, 98
risk of hyperkalemia and cardiac arrest 137
sugammadex, mechanism of action 107–108, 107
suicidal hanging (non-lethal), common presenting injuries 471
sulfamylon acetate antimicrobial, side effects 427–428
sulfonylurea overdose, symptoms and treatment 247–248
systemic inflammatory response syndrome (SIRS) causes and treatment 20
diagnostic criteria 20, 51
systemic vascular resistance (SVR) calculation 67
definition 67
t-test 484
tachycardia, diagnosis 34–35, 34
tacrolimus drug-drug interactions 209–210, 210
immunosuppression in transplant patients 210
mechanism of action 214–215
side effects 215
Takotsubo’s syndrome 36
tazobactam, antimicrobial activity 105–106
telemedicine and telepresence for surgery and trauma 477–481
applications for surgical telementoring 477–478
benefits of implementation in critical care units 481
electronic data communications networks 477
real-time trauma resuscitation 480–481
teletrauma support 479–480
virtual intensive care 478–479
temperature management, intravascular versus surface cooling 157
temporary abdominal closure (TAC), methods and considerations 312–313
temporary intravascular shunt (TIVS) duration of placement 329–330
in combined skeletal and arterial injuries 333–334, 334
purpose of 329–330
tension pneumothorax diagnosis and management 447
effect on central venous pressure (CVP) 66
tetanus, treatment for patients at risk 54
therapeutic hypothermia, indications and contraindications 155
thermodilution principle, use in pulmonary artery catheter 62–63
thiopental, mechanism of action 128
thoracic surgery 439–451
thoracic vascular injury 299–306
thoracotomy, indications for urgent/emergent thoracotomy 303
thrombocytopenia, heparin‐induced (HIT) 100–101, 115–116
thromboelastography (TEG), use of rapid TEG in trauma patients 112, 117
thrombotic thrombocytopenic purpura (TTP), pregnant patient 222–223
thymoglobulin, side effects when used as induction agent 216–217
thyroid storm, etiologies, symptoms and management 148
tibia and fibula fracture
indication for below‐knee amputation 320
indications of compartment syndrome 321
limb salvage versus amputation 320
pain following splinting 321
tibia fracture
fasciotomy incision to decompress the leg compartments 322
infection risk in open fractures 319–320, 319
 timing of debridement of open fractures 320
tigecycline
black box warning 108
risk of death 108
use in refractory C. difficile infection 100
time‐to‐event analysis 488–489, 489
Tobin index 86
tocolytic associated pulmonary edema 226
torsade de pointes 41–42, 41–42
total parenteral nutrition (TPN) constituents of 185
efficacy in critically‐ill and injured patients 181–182
formulas 180
guidelines on lipid use 182
hypophosphatemia risk 141–142
indications for the use of 180–181
prophylactic antibiotics 93
refeeding syndrome 141–142
tourniquet, use to control active bleeding 328–329
toxic shock syndrome, choice of antibiotic 107
toxicology 239–251
toxidromes
management strategies 240–241
salicylate poisoning 241–242
signs for specific drug classes 240–241
tracheal injury
airway management 297
“clothesline” injury management 297
penetrating injury 289–290
tracheal laceration repair 292
tracheal intubation, actions following several failed attempts 293–294
tracheoesophageal fistula (TEF) diagnosis and management 448–449
in intubated patients 448–449
tracheo‐innominate fistula (TIF) diagnosis and treatment 445–446
risk factors in tracheostomy 294–295
tracheostomy
bleeding after the first 48 hours 445
choice of technique 256–257
complication rates in obese patients 416
management of a dislodged tracheostomy tube 84
ongoing hemorrhage from 445–446
potential early and late complications 257
risk factors for tracheo‐innominate fistula 294–295
tranexamic acid (TXA), use in trauma patients 110–111
transferrin, function as a negative acute phase protein 178–179
transfusion 109–119
activation of massive transfusion protocol (MTP) 111–112
blood component therapy 109
definition of massive transfusion 111–112
effects of liberal transfusion with PRBCs 111
plasma for patient of unknown blood type 112–113
PRBC transfusion in pediatric critically‐ill patients 228–229
prophylactic transfusion in trauma patients 109–110
ratio and type of platelets 113
respiratory distress during or after 110
restrictive transfusion strategy 109–110
stable trauma patient without active bleeding 109–110
use of rapid thromboelastography (TEG) in trauma patients 112, 117
use of uncrossmatched type O blood in trauma patients 118
see also massive transfusion
transfusion‐associated acute lung injury (TRALI) 110
transfusion‐associated circulatory overload (TACO) 110
transjugular intrahepatic portosystemic shunt (TIPS) stent stenosis risk 171
use in intractable ascites 173
transplantation 209–217
hyperacute rejection 213–214
treatment of cytomegalovirus (CMV) infection 215–216
transanchothoracic echocardiography (TTE), assessment of pericardial effusion 261
trans‐tracheal jet ventilation (TTJV) 293–294
trauma patients
risk factors for developing pneumonia 94
use of tranexamic acid (TXA) 110–111
traumatic brain injury (TBI)
avoiding secondary brain injury 191
Brain Injury Guidelines (BIG) 284–285
brain oxygenation monitoring techniques 195
Brain Trauma Foundation management guidelines 198
criteria for brain death declaration 494–495
decompressive craniectomy 283–284
decreasing ICP without lowering BP 284
disruption of cerebral autoregulation 196
effects of fever in neurological injury 156
identification in pediatric patients 463–464
initial management of acute head injury 277–279
initial treatment of severe TBI 280
intracranial pressure (ICP) monitoring 279
management guidelines 191
management of anticoagulated patients 285–286
management of cerebral perfusion pressure 196
management of elevated ICP in pediatric patients 196–197
management of small injuries 284–285
management using Brain Injury Guidelines (BIG) 284–285
objective of ICP monitoring 189–190
optimizing ICP and cerebral perfusion pressure (CPP) 283–284
predictor of poor outcome in gunshot wound to the brain 191–192
pregnant trauma patient 348
recommended target cerebral perfusion pressure 280
role of steroid therapy 189
seizures following 194
therapy for increased intracranial pressure (ICP) 280–281
use of barbiturate therapy 194–195
use of hypertonic saline 284
use of progesterone therapy 196
VTE risk and prophylaxis 283
traumatic diaphragmatic hernia (TDH), causes and presentation 299
traumatic head injury, drugs for rapid-sequence intubation 72–73
traumatic venous injury, options for repair 332
tricuspid regurgitation, right atrial tracing 8, 9, 10
tricyclic antidepressants (TCA) clinical presentation of TCA toxicity in overdose 239–240
management of TCA overdose 471
suicide risk in elderly people 471
triple contrast CT scan, indications and contraindications 267–268
Trousseau sign 145
tubocurarine, metabolism and elimination 72
Type I error 485
Type II error 485
typhlitis, complication of chemotherapy 374–375
ultrasound 261–272
guidance for central venous catheter (CVC) placement 270–271
use in initial assessment of trauma patients 262
umbilical hernia fluid leakage in patient with cirrhosis 404–405
incarcerated/strangulated 381
reduction of incarceration and repair 403
unfractionated heparin (UFH) anticoagulation 99–100
United States Uniform Anatomic Gift Act 496
unrecognised misplaced intubation (UMI), identifying 64–65
uremic bleeding, coagulopathy in uremic patients 116
ureteral injury from gunshot wound, treatment options 341–342
urethral injury diagnosis in trauma patients 308
indications and investigation 337–338, 339
management of anterior and posterior urethral injuries 340
urinary tract infection (UTI), risk factors in catheterized patients 93–94
urologic trauma and disorders 337–343
valproic acid overdose, symptoms and management 246
vancomycin antimicrobial action 104
use in refractory C. difficile infection 100
use in VAP 104–105
vancomycin-resistant Enterococcus (VRE), association with VAP 96
vascular injury abdominal 307–315
evaluation and management 327
hard and soft signs 327
thoracic 299–306
vascular resistance, definition 67
vasoconstriction, role of endothelin-1 in cardiogenic shock 58
vasodilation cause in sepsis 57–58
effects of nitric oxide (NO) 57–58
effects of vasodilators on cardiac function 3
mechanism of action of dobutamine 62
vasopressor 15
role in septic shock management 56–57, 91–92
vasopressor-dependent septic shock, use of corticosteroids 52
vecuronium mechanism of action 122, 123
metabolism and elimination 72, 98
reversal drugs 107–108
venous access catheters, factors influencing optimal rate of volume resuscitation 3, 4
venous thromboembolism (VTE) ACCP prevention and treatment guidelines 205, 206
characteristics of VTE in pregnancy 223
incidence in the SICU 207
risk factors in pediatric patients 463
risk factors in pediatric trauma patients 232–233
risk in pregnancy and post-partum 201–202
venous thromboembolism (VTE) prophylaxis criteria in pediatric patients 463
tenoxaparin dosing and monitoring 207
in traumatic brain injury patients 283
ventilated patient, oxygen uptake/consumption (VO₂) calculation 18
ventilator-associated pneumonia (VAP) choice and dose of antimicrobial agent 104
common causative organisms 55, 96
diagnosis 81
diagnostic criteria for quantitative microbiology 52
diagnostic use of bronchoscopy 258
duration of antibiotic therapy 90
empiric therapy 96
Infected Disease Society of America (IDSA) guidelines for management 104–105, 104
pathogens associated with early-onset VAP 52
prevention bundles 91
risk factors for MDR pneumonia 96
risk factors in the pediatric ICU 232
risk of multidrug resistant (MDR) pathogens 104–105, 104
sources of causative bacteria 53
use of hospital antibiograms 104
ventilator support 79–88
addressing “bird’s beak” pressure-volume curve 88, 88
 cardiopulmonary interactions 12–13
findings before postoperative spontaneous breathing begins 83
indicators for successful liberation from support 64
intraoperative ventilatory settings 83
management of respiratory acidosis 84
managing elderly patients 466
optimal level of sedation 127, 127
pneumothorax–pleural fistula (PPF) management 82
rapid shallow breathing index (RSBI) 64
waveform analysis 87, 87
ventilator tidal volume setting for obese patients 416
ventral hernia, principles for repair 405
ventricular fibrillation Brugada syndrome 35–36, 35
following myocardial infarction 49–50, 49
ventriculoseptal defect (VSD), post-myocardial infarction 44–45, 45
ventriculostomy, management of elevated intracranial pressure 190
ventriculostomy catheters, incidence of infection from 192–193
vertebral artery, management of traumatic injury 295–296, 295
Vibrio species, diagnosis of NSTI caused by 412
Vibrio vulnificus association with NSTIs 94–95
symptoms and treatment of infection from seafood 211–212
video laryngoscopy, effect on first-chance intubation success rate 70
violence towards pregnant women, risk factors and consequences 435
virtue ethics 492–493, 495
vitamin B12 deficiency, risks related to nitrous oxide anesthesia 124
volume-cycled ventilation (VCV), prolonging the inspiratory time 81–82
volume resuscitation, management of continued hypoperfusion 91
volume status indicators 60
management in trauma patients 340
vomiting, acid-base and electrolyte abnormalities caused by 136
VTE see venous thromboembolism W
warfarin anticoagulation rapid reversal in trauma patients 114
use in elderly trauma patients 466–467
weaning from sedation 121–122
Wells score for PE diagnosis 204
West lung zones 12
Westermark sign 80
whole bowel irrigation (WBI), prevention of absorption of drugs 239
Wilcoxon Rank Sum test 484, 485
Wolf–Parkinson–White syndrome 34–35, 34
wound healing, impairment in steroid-treated patients 149–150
wrist injury, factors leading to poor outcomes 325
wrist pain occult scaphoid fracture 323
without acute radiographic findings 323
wrong-site surgical procedures protocol to prevent 73
risk factors for 73
X
Xarelto see rivaroxaban
X-ray, use in pelvic fracture diagnosis 271